نتایج جستجو برای: Taxus

تعداد نتایج: 1272  

Journal: :JACC. Cardiovascular interventions 2008
Mark A Turco John A Ormiston Jeffrey J Popma Jack J Hall Tift Mann Louis A Cannon Mark W I Webster Gregory J Mishkel Charles D O'Shaughnessy Thomas F McGarry Lazar Mandinov Keith D Dawkins Donald S Baim

OBJECTIVES The TAXUS ATLAS Small Vessel (SV) and Long Lesion (LL) multicenter studies compared the performance of the thin-strut (0.0038 inch) TAXUS Liberté 2.25-mm stent (Boston Scientific; Natick, Massachusetts) and the TAXUS Liberté 38-mm long stent (Boston Scientific; Natick, Massachusetts) with the earlier paclitaxel-eluting TAXUS Express (Boston Scientific) stent that has identical polyme...

2013
Jang-Won Son Ung Kim Jong-Seon Park Young-Jo Kim Jae-Sik Jang Tae-Hyun Yang Dong-Soo Kim Dong-Kie Kim Sang-Hoon Seol Doo-Il Kim Chang-Wook Nam Seung-Ho Hur Kwon-Bae Kim

BACKGROUND/AIMS The Taxus Liberte stent (Boston Scientific Co.) evolved from the Taxus Express stent, with enhanced stent deliverability and uniform drug delivery. This study was designed to compare angiographic and clinical outcomes in real-world practice between the Taxus Liberte and Taxus Express stents. METHODS Between 2006 and 2008, 240 patients receiving the Taxus Liberte stent at three...

2015
Prashant Saxena

Taxol is a known drug, approved by the food and drug administration in 1992 for the treatment of a wide range of cancers. Taxol is obtained from the taxus plant. Taxus plant has a very long life cycle and the production of taxol from the plant is a tedious process. In this study, we have tried to find new species of taxus which can be able to produce taxol and can overcome the burden of Taxus b...

Journal: :Circulation 2009
Sigmund Silber Antonio Colombo Adrian P Banning Karl Hauptmann Janusz Drzewiecki Eberhard Grube Dariusz Dudek Donald S Baim

BACKGROUND The TAXUS II trial was designed to evaluate the safety and efficacy of the commercialized slow-release (SR) and an investigation-only moderate-release (MR) polymer-based TAXUS paclitaxel-eluting stent compared with a bare-metal stent for the treatment of de novo coronary lesions. METHODS AND RESULTS This prospective, randomized, double-blind, controlled trial enrolled 536 patients ...

Journal: :American heart journal 2012
Kirk N Garratt David P Lee Eileen M Rose Kellie J Windle Hsini Liao Chuke E Nwachuku Kenneth J Winters Thomas S Bowman Keith D Dawkins

BACKGROUND Observational studies of new coronary stents are necessary to assess performance in a variety of complex patient and lesion types. Furthermore, the optimal dose and duration of thienopyridine treatment is unclear, particularly in patients with complex clinical conditions. The TAXUS Libertē Post-Approval Study is designed to provide 5-year data on the TAXUS Liberté paclitaxel-eluting ...

Journal: :European heart journal 2008
Lisette Okkels Jensen Michael Maeng Per Thayssen Evald Hoej Christiansen Knud Noerregaard Hansen Anders Galloe Henning Kelbaek Jens Flensted Lassen Leif Thuesen

AIMS Patients with diabetes have increased risk of in-stent restenosis after coronary stent implantation owing to neointimal hyperplasia (NIH). The aim of the study was to evaluate the extent and distribution of NIH with intravascular ultrasound (IVUS) after coronary artery stenting with sirolimus-eluting (Cypher) or paclitaxel-eluting (Taxus) stents in diabetic patients. METHODS AND RESULTS ...

2010
Juan F Granada Barbara A Huibregtse Keith D Dawkins

Patients with diabetes mellitus, of female gender, increased age, and/or with peripheral vascular disease often develop coronary stenoses in small caliber vessels. This review describes treatment of these lesions with the paclitaxel-eluting 2.25 mm TAXUS(®) Liberté(®) Atom™ stent. Given the same stent composition, polymer, antirestenotic drug (paclitaxel), and release kinetics as the first-gene...

Journal: :European heart journal 2007
Eberhard Grube Keith D Dawkins Giulio Guagliumi Adrian P Banning Krzysztof Zmudka Antonio Colombo Leif Thuesen Karl Hauptman Jean Marco William Wijns Jeffrey J Popma Lutz Buellesfeld Joerg Koglin Mary E Russell

AIMS Drug-eluting stents (DESs) have shown to be effective in reducing in-stent restenosis, although data relating to long-term experience in treating more complex lesion subsets are limited. In order to assess the long-term safety and clinical efficacy of the polymer-based moderate release (MR) paclitaxel-eluting TAXUS MR stent in treatment of complex lesion subsets, we evaluated the 2-year fo...

Journal: :Circulation 2003
Eberhard Grube Sigmund Silber Karl Eugen Hauptmann Ralf Mueller Lutz Buellesfeld Ulrich Gerckens Mary E Russell

BACKGROUND The TAXUS NIRx stent (Boston Scientific Corp) provides local delivery of paclitaxel via a slow-release polymer coating. The TAXUS I trial was the first in-human experience evaluating safety and feasibility of the TAXUS NIRx stent system compared with bare NIR stents (control) (Boston Scientific Corp) for treatment of coronary lesions. METHODS AND RESULTS METHODS AND RESULTS The ...

Journal: :Trials 2009
Jae-Bin Seo Hui-Kyung Jeon Kyung-Woo Park Jong-Seon Park Jang-Ho Bae Sang-Wook Kim Keon-Woong Moon Jae-Woong Choi Sang-Gon Lee Woo-Young Chung Tae-Jin Youn Soo-Joong Kim Doo-Il Kim Byung-Ok Kim Min-Su Hyon Keum-Soo Park Tae-Joon Cha Hweung-Kon Hwang Seung-Ho Hur Hyo-Soo Kim

BACKGROUND Previous randomized trials have showed the superiority of Paclitaxel-eluting stent over bare metal stent in angiographic and clinical outcomes. Coroflex Please stent is a newly developed drug eluting stent using the Coroflex stent platform combined with the drug paclitaxel contained in a polymer coating. PECOPS I trial, one-arm observational study, showed that the clinical and angiog...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید